IMNM · ISSUER CIK 1472012
Immunome Inc.
Between Aug 1, 2026 and Oct 29, 2026, 3 Immunome Inc. insiders reported $0.00 of open-market purchases and $5.7M of sales on SEC Form 4.
↗3 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 4 of 4 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$5.7MInsider selling
−$5.7MNet open-market
Sep 15, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 202616:30 | Sep 11, 2026 | IMNM | Chief Scientific Officer | S · Sell10b5-1 | $25.32 | −13,200 | 65,050 | -17% | −$334K | ||
| Sep 15, 202616:30 | Sep 11, 2026 | IMNM | Chief Scientific Officer | M · Exercise10b5-1 | $1.35 | +18,000 | 78,250 | +30% | $24K | ||
| Sep 15, 202616:30 | Sep 11, 2026 | IMNM | Chief Scientific Officer | G · Gift10b5-1 | — | −8,800 | 56,250 | -14% | — | ||
| Aug 12, 202617:47 | Aug 12, 2026from Aug 10, 2026 | IMNM | Director | S · Sell10b5-1 | $26.35 | −83,464 | 92,211 | -48% | −$2.2M | ||
| Aug 10, 202616:10 | Aug 7, 2026from Aug 6, 2026 | IMNM | Director | S · Sell10b5-1 | $26.06 | −36,088 | 72,416 | -33% | −$940K | ||
| Aug 6, 202618:30 | Aug 4, 2026 | IMNM | CHIEF BUSINESS OFFICER | S · Sell10b5-1 | $25.09 | −90,616 | 0 | -100% | −$2.3M | ||
| Aug 6, 202618:30 | Aug 4, 2026 | IMNM | CHIEF BUSINESS OFFICER | M · Exercise10b5-1 | $11.89 | +90,616 | 90,616 | New | $1.1M |